Verismo Therapeutics Inc. has submitted an IND application to the FDA seeking to initiate a phase I trial this year of Synkir-310 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL), including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma.
Researchers from China Pharmaceutical University published data detailing the discovery and preclinical evaluation of novel tubulin polymerization inhibitors as potential anticancer agents.
Discovery of novel Nav1.8 inhibitors capable of achieving high levels of target modulation at low oral doses for the potential treatment of pain was reported by Merck & Co. Inc.
Hypoxia-inducible factor 2α (HIF-2α) is a transcription factor that plays a key role in oxygen homeostasis and response to tumor hypoxic microenvironment of cancer cells. Previous research has suggested that inhibition of HIF-2α is a promising antitumor approach, particularly against tumors associated with mutant von Hippel-Lindau (pVHL).
Alterome Therapeutics Inc. has closed a $132 million series B financing to support the advancement of its pipeline of next-generation, small-molecule targeted cancer therapies into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor.
Cytomx Therapeutics Inc. has announced the nomination of the second clinical candidate under its Probody T-cell engaging bispecific (TCB) collaboration with Astellas Pharma Inc. The two companies are collaborating on multiple conditionally activated TCB programs, with T-cell engagers offering new possibilities for the treatment of solid tumors.
Natural killer (NK) cells play a crucial role in cancer immunosurveillance. Circulating NK cells can kill target cells without prior sensitization. There are some receptors known to impact the activity of NK cells, such as the inhibitory NK cell receptor TIM3, among others, which recognizes phosphatidylserine on the surface of cells. More research has been performed using targeted or genome-wide CRISPR screening to identify cancer cell genes that impact NK cell-killing ability.
After decades of trying and dozens of failed trials, amyloid targeting has paid off with the first disease-modifying agents reaching the market. But success does not mean slam dunk. Aduhelm (aducanumab, Biogen Inc.) was dogged by controversy throughout its brief tenure, and Biogen pulled the plug on it in early 2024. Leqembi (lecanemab, Biogen Inc.) has received full approval. In this second installment of a three-part series on Alzheimer’s, BioWorld looks at the nuanced view of amyloid’s role in the disease.
FmlH is a bacterial adhesin of uropathogenic E. coli (UPEC) that has been shown to be up-regulated during chronic UPEC infection. Washington University scientists recently disclosed the discovery and preclinical evaluation of novel FmlH lectin antagonists as potential candidates for the treatment of chronic urinary tract infections (UTIs) and kidney infections.
Exscientia plc has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, gout, inflammatory and neurological disorders, psoriasis and sickle cell disease.
RSS
